Dengue encephalitis

 

We are just recovering from the SARS CoV2 pandemic and the dengue season is upon us! The wards and the out-patients are full of patients with Dengue. It appears there are many more children with serious complications this year than we usually see.

A 12 year old boy came in with fever and body aches for 5 days and altered sensorium for 2 days. The Dengue NS1 antigen was positive, platelet count was low and his transaminases were mildly elevated.

His MRI Brain had the classic splenial hyper intensity on T2/ FLAIR and also showed diffusion restriction.

For a long time it was debated whether the dengue virus actually infects the central nervous system. However documentation of the RNA virus in the CSF in the absence of serum viral copies suggests that the dengue virus can occasionally be neurotropic.

Of course, encephalopathy due to shock, metabolic derangements like hyponatremia, hepatic and renal dysfunctions are certainly commoner than actual encephalitis.

Other neurological manifestations include myositis, immune mediated disorders ( eg ADEM, GBS, transverse myelitis and the Miller Fischer syndrome) and neuro-ophthalmic manifestations ( eg uveitis, maculopahty, optic neuritis).https://doi.org/10.1016/S1474-4422(13)70150-9

The transient splenic hyper intensity is thought to be due to intramyelinic edema and is seen in many other conditions such as influenza related encephalopathy, seizures, demyelination and hypoglycaemia.

There are no specific antivirals available for dengue though pulse methyl prednisolone and IVIG have been used for the immune mediated neurological dysfunctions due to dengue.

Mortality can be as high as 30%.

Risdiplam- the oral drug for SMA

 

My patient with SMA type 2 rushed into my OPD very excited that his child was going to receive Risdiplam free as part of a clinical trial. "How safe is it ? Is it effective?"he was bombarding me with questions.

So that night I sat down to read about it, so I could give him a more educated answer.

The FDA approved Risdiplam (Everysdi by Roche) in August 2020 for use in adults and children above 2 months with SMA.

The most exciting fact is that it is given orally unlike Nusirensin which has to be given intrathecally.

The approval is based on 2 clinical studies. 

The first trial was FIREFISH done on symptomatic infants between 2- 7 months. 41% ( 7/17 babies learnt to sit and 90% were alive without ventilation at 12 months.

In the other trial SUNFISH which was a placebo controlled trial in patients between 2-25 years there was a statistically significant improvement in motor function.

How does it work?  Normally the SMN2 is spliced such that in 85% exon 7 is excluded resulting in a small and easily degradable protein. Risdiplam promoted splicing in SMN2 to allow inclusion of exon 7, resulting in a functional protein. This is able to fill the deficiency of SMN1 protein.

Fever, diarrhoea, rashes and oral ulcers are some minor adverse events documented so far.

Hereditary Hyperekplexia: what should we know?

A 3 month old baby born of a third degree consanguineous marriage, came in with the history of recurrent episodes of tonic posturing and stiffness since day 1 of life. Mother noticed that whenever she was tapped on the nose she would become stiff ( The Nose Tap Test). Sometimes the episode was so prolonged, she would get cyanosed. Neuroimaging and EEG were normal. She had also developed an umbilical hernia because of the recurrent stiffening episodes.

The diagnosis was a no-brainer. Hereditary Hyperekplexia however is often misdiagnosed as tonic seizures. I demonstrated the Vigevano manoeuvre to the mother. Forcibly flexing the head and legs towards the abdomen aborts the episode and is life-saving. Response to clonazepam (0.01-0.1 mg/kg) is most gratifying. Combination clobazam ( upto 2 mg/kg) plus clonazepam has been used in refractory cases. Fluoxetine and alcohol has been used in adult. Cannabidiol and ondansetron  are under investigation.

A beautiful analysis of 97 patients with genetically proven hyperekplexia yielded some useful genotype -phenotype correlations:https://doi.org/10.1093/brain/awt207

The commonest genetic variants were seen in the GLRA1 gene

Infantile apnoea were common in SLC6A5 mutations

92% of patients with GLRB mutations had delayed speech, even autism

Both GLRB and SLC6A5 were more likely to have developmental delay than GLRA1.

 

A treatable myopathy- late onset Pompe's

 A 2 year old girl with normal birth and development came in with the history of inability to get up from squatting and difficulty in climbing stairs for the past 4 months. She had no muscle pain or tenderness and no calf muscle hypertrophy. Her CPK was 700 ugm/L and LDH was 1394 U/L, both moderately elevated.

Her EMG was myopathic. Her workup for autoimmune myositis was negative. However her DBS screening for Pompe's disease showed low levels of acid alpha glycosidase (GAA). We decided to do genetic studies to confirm the diagnosis.

Late onset Pompe's is often not in our radar for children presenting with proximal myopathy.

What are the clinical clues to trigger its consideration in a clinicians mind?

It predominantly affects the hip girdle muscles such as the hip adductors and flexors.

A peculiarity is the involvement of the paraspinal muscles. Sometimes they have back pain or a rigid spine. Myotonic discharges from the paraspinal muscles are considered a good clue to the diagnosis.

The relative involvement of the diaphragm and accessory muscles of respiration results clinically in recurrent pneumonias. Nocturnal hypoventilation may present as early morning headaches. You can check for a decline in oxygen saturation and FVC ( > 10% fall) in the supine position which is a good screen for diaphragmatic involvement. 

Unlike the classic Pompe's disease the heart is not involved except for stray reports of WPW syndrome.

Neither do they have hepatomegaly or macroglossia.

Enzme levels range between 1-40% of normal.

Most importantly early use of enzyme replacement makes a significant difference in what would otherwise be progressive decline in muscle function. https://www.aanem.org/mxonline/resources/downloads/products/ED01.pdf